CO2021007993A2 - Compuestos de 2‐formil‐3‐hidroxifeniloximetilo capaces de modular la hemoglobina - Google Patents

Compuestos de 2‐formil‐3‐hidroxifeniloximetilo capaces de modular la hemoglobina

Info

Publication number
CO2021007993A2
CO2021007993A2 CONC2021/0007993A CO2021007993A CO2021007993A2 CO 2021007993 A2 CO2021007993 A2 CO 2021007993A2 CO 2021007993 A CO2021007993 A CO 2021007993A CO 2021007993 A2 CO2021007993 A2 CO 2021007993A2
Authority
CO
Colombia
Prior art keywords
hydroxyphenyloxymethyl
formyl
compounds capable
hemoglobin
modulating
Prior art date
Application number
CONC2021/0007993A
Other languages
English (en)
Inventor
Zhe Li
Original Assignee
Global Blood Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Global Blood Therapeutics Inc filed Critical Global Blood Therapeutics Inc
Publication of CO2021007993A2 publication Critical patent/CO2021007993A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La presente descripción se refiere en general a compuestos y composiciones farmacéuticas adecuadas como moduladores de la hemoglobina, y a métodos para su uso en el tratamiento de trastornos mediados por la hemoglobina.
CONC2021/0007993A 2018-11-19 2021-06-18 Compuestos de 2‐formil‐3‐hidroxifeniloximetilo capaces de modular la hemoglobina CO2021007993A2 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862769196P 2018-11-19 2018-11-19
US201962821314P 2019-03-20 2019-03-20
US201962848773P 2019-05-16 2019-05-16
US201962883313P 2019-08-06 2019-08-06
PCT/US2019/062054 WO2020106642A1 (en) 2018-11-19 2019-11-18 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin

Publications (1)

Publication Number Publication Date
CO2021007993A2 true CO2021007993A2 (es) 2021-06-30

Family

ID=68848454

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0007993A CO2021007993A2 (es) 2018-11-19 2021-06-18 Compuestos de 2‐formil‐3‐hidroxifeniloximetilo capaces de modular la hemoglobina

Country Status (29)

Country Link
US (3) US10683285B2 (es)
EP (2) EP4046988A1 (es)
JP (1) JP7509772B2 (es)
KR (1) KR102842589B1 (es)
CN (1) CN113316568B (es)
AU (1) AU2019383960B2 (es)
BR (1) BR112021007044B1 (es)
CA (1) CA3120380A1 (es)
CO (1) CO2021007993A2 (es)
CR (1) CR20210335A (es)
CY (1) CY1125025T1 (es)
DK (1) DK3880654T3 (es)
ES (1) ES2908325T3 (es)
HR (1) HRP20220295T1 (es)
HU (1) HUE057323T2 (es)
IL (1) IL283128B2 (es)
LT (1) LT3880654T (es)
MA (1) MA54231B1 (es)
MD (1) MD3880654T2 (es)
MX (1) MX2021005887A (es)
PL (1) PL3880654T3 (es)
PT (1) PT3880654T (es)
RS (1) RS62970B1 (es)
SA (1) SA521422031B1 (es)
SG (1) SG11202104705RA (es)
SI (1) SI3880654T1 (es)
SM (1) SMT202200106T1 (es)
TW (1) TWI841630B (es)
WO (1) WO2020106642A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2890077T3 (es) 2013-03-15 2022-01-17 Global Blood Therapeutics Inc Compuestos y usos de los mismos para la modulación de la hemoglobina
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AU2014237330A1 (en) 2013-03-15 2015-09-17 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AU2014237340C1 (en) 2013-03-15 2018-11-08 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
PL3102208T5 (pl) 2014-02-07 2024-10-14 Global Blood Therapeutics, Inc. Krystaliczny polimorf wolnej zasady 2-hydroksy-6-((2-(1-izopropylo-1h-pirazol-5-ilo)pirydyn-3-ylo)metoksy)benzaldehydu
PL3383392T3 (pl) 2015-12-04 2025-11-17 Global Blood Therapeutics, Inc. Schematy dawkowania dla 2-hydroksy-6-((2-(1-izopropylo-1H-pirazol-5-ilo)pirydyn3-ylo)metoksy)benzaldehydu
US11014927B2 (en) 2017-03-20 2021-05-25 Forma Therapeutics, Inc. Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
MA53668B1 (fr) 2018-09-19 2024-06-28 Novo Nordisk Health Care Ag Traitement de la drépanocytose avec un composé activant la pyruvate kinase r
JP7450610B2 (ja) 2018-09-19 2024-03-15 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー ピルビン酸キナーゼｒの活性化
ES2966707T3 (es) 2018-10-01 2024-04-23 Global Blood Therapeutics Inc Moduladores de la hemoglobina para el tratamiento de la drepanocitosis
WO2020106642A1 (en) * 2018-11-19 2020-05-28 Global Blood Therapeutics, Inc. 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin
MA57202B1 (fr) 2019-09-19 2025-09-30 Novo Nordisk Health Care Ag Compositions d'activation de la pyruvate kinase r (pkr)
WO2021202284A1 (en) * 2020-03-31 2021-10-07 Global Blood Therapeutics, Inc. Modulators of hemoglobin
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
IL307906A (en) * 2021-05-14 2023-12-01 Global Blood Therapeutics Inc Methods for preparing a hemoglobin modulator
JP2024520897A (ja) * 2021-05-14 2024-05-27 グローバル ブラッド セラピューティクス インコーポレイテッド ヘモグロビン調節因子の固体形態
JP2024527819A (ja) 2021-07-19 2024-07-26 バイオアプリケーションズ インコーポレイテッド 植物由来のｃｏｖｉｄ－１９変異組換えスパイクタンパク質発現ベクターおよび該発現ベクターを用いた組換えタンパク質
KR20240116826A (ko) * 2021-12-10 2024-07-30 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈의 조정제의 투여 방법
TW202515579A (zh) 2023-06-13 2025-04-16 美商全球血液治療公司 投予血紅素的調節劑之方法
WO2025262596A1 (en) * 2024-06-20 2025-12-26 Pfizer Inc. Methods of making osivelotor

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
JPS5649335A (en) 1979-06-29 1981-05-02 Wellcome Found Ether compound
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
GR76950B (es) 1980-12-18 1984-09-04 Wellcome Found
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
JPS63258463A (ja) 1987-04-14 1988-10-25 Kumiai Chem Ind Co Ltd ２−フエノキシピリミジン誘導体及び除草剤
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
EP0658559A1 (de) 1993-12-14 1995-06-21 Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. Thienothiazinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als 5-dipoxygenase und Cyclooxygenaseinhibitoren
WO2000035858A1 (en) 1998-12-14 2000-06-22 F. Hoffmann-La Roche Ag Phenylglycine derivatives
PL350769A1 (en) 1999-03-31 2003-01-27 Basf Ag Substituted aniline compounds
US20060074119A1 (en) 2002-08-08 2006-04-06 Andrews Clarence W Iii Thiophene compounds
EP2179987B1 (en) 2002-12-04 2013-02-13 Virginia Commonwealth University Use of heterocyclic carbaldehyde derivatives against sickle cell anemia
BRPI0411255A (pt) 2003-06-12 2006-08-01 Novo Nordisk As composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
US20070293698A1 (en) 2004-04-22 2007-12-20 Allos Therapeutics, Inc. Compositions of Allosteric Hemoglobin Modifiers and Methods of Making the Same
KR20080027908A (ko) 2005-06-30 2008-03-28 프로시디온 리미티드 Ｇｐｃｒ 효능제
CN100562514C (zh) 2005-07-22 2009-11-25 中国科学院上海药物研究所 一类取代丙酰胺衍生物、其制备方法和用途
WO2008066145A1 (en) 2006-11-30 2008-06-05 R-Tech Ueno, Ltd. Thiazole derivative and use thereof as vap-1 inhibitor
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
KR101538822B1 (ko) 2008-05-08 2015-07-22 노바 사우쓰이스턴 유니버시티 혈관 내피 성장 인자 수용체에 대한 특이적 억제제
GB0811451D0 (en) 2008-06-20 2008-07-30 Syngenta Participations Ag Novel microbiocides
TW201033201A (en) 2009-02-19 2010-09-16 Hoffmann La Roche Isoxazole-isoxazole and isoxazole-isothiazole derivatives
PT3141542T (pt) 2011-12-28 2020-06-16 Global Blood Therapeutics Inc Compostos de benzaldeído substituído e métodos para a sua utilização no aumento da oxigenação de tecidos
EP2797597B1 (en) 2011-12-28 2020-02-26 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
AU2014237340C1 (en) 2013-03-15 2018-11-08 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20140271591A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compositions and methods for the modulation of hemoglobin (s)
US20150057251A1 (en) 2013-08-26 2015-02-26 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
ES2890077T3 (es) 2013-03-15 2022-01-17 Global Blood Therapeutics Inc Compuestos y usos de los mismos para la modulación de la hemoglobina
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) * 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EP2970315B1 (en) * 2013-03-15 2021-09-15 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2015031284A1 (en) 2013-08-26 2015-03-05 Global Blood Therapeutics, Inc. Formulations comprising wetting agents and compounds for the modulation of hemoglobin (s)
US20160207904A1 (en) 2013-08-27 2016-07-21 Global Blood Therapeutics, Inc. Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts
US20150141465A1 (en) 2013-11-18 2015-05-21 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
US9248199B2 (en) 2014-01-29 2016-02-02 Global Blood Therapeutics, Inc. 1:1 adducts of sickle hemoglobin
PL3102208T5 (pl) 2014-02-07 2024-10-14 Global Blood Therapeutics, Inc. Krystaliczny polimorf wolnej zasady 2-hydroksy-6-((2-(1-izopropylo-1h-pirazol-5-ilo)pirydyn-3-ylo)metoksy)benzaldehydu
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
PL3383392T3 (pl) 2015-12-04 2025-11-17 Global Blood Therapeutics, Inc. Schematy dawkowania dla 2-hydroksy-6-((2-(1-izopropylo-1H-pirazol-5-ilo)pirydyn3-ylo)metoksy)benzaldehydu
TWI663160B (zh) 2016-05-12 2019-06-21 全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
WO2020106642A1 (en) * 2018-11-19 2020-05-28 Global Blood Therapeutics, Inc. 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin

Also Published As

Publication number Publication date
WO2020106642A1 (en) 2020-05-28
DK3880654T3 (da) 2022-03-07
US20200157085A1 (en) 2020-05-21
MA54231A (fr) 2021-09-22
KR20210093990A (ko) 2021-07-28
US20230159507A1 (en) 2023-05-25
IL283128A (en) 2021-06-30
IL283128B2 (en) 2025-03-01
SMT202200106T1 (it) 2022-05-12
TW202039460A (zh) 2020-11-01
SI3880654T1 (sl) 2022-04-29
EP3880654A1 (en) 2021-09-22
TWI841630B (zh) 2024-05-11
BR112021007044B1 (pt) 2022-04-19
AU2019383960A1 (en) 2021-06-10
SA521422031B1 (ar) 2023-12-24
MA54231B1 (fr) 2021-12-31
AU2019383960B2 (en) 2024-10-10
CA3120380A1 (en) 2020-05-28
JP7509772B2 (ja) 2024-07-02
LT3880654T (lt) 2022-02-25
MX2021005887A (es) 2021-09-14
SG11202104705RA (en) 2021-06-29
PT3880654T (pt) 2022-04-08
WO2020106642A8 (en) 2020-12-30
EP3880654B1 (en) 2021-12-29
HUE057323T2 (hu) 2022-04-28
CN113316568A (zh) 2021-08-27
KR102842589B1 (ko) 2025-08-04
MD3880654T2 (ro) 2022-05-31
BR112021007044A2 (pt) 2021-07-27
US11548880B2 (en) 2023-01-10
RS62970B1 (sr) 2022-03-31
ES2908325T3 (es) 2022-04-28
EP4046988A1 (en) 2022-08-24
US20210047309A1 (en) 2021-02-18
PL3880654T3 (pl) 2022-04-25
CR20210335A (es) 2021-09-14
JP2022509091A (ja) 2022-01-20
US10683285B2 (en) 2020-06-16
CN113316568B (zh) 2024-11-08
CY1125025T1 (el) 2023-03-24
HRP20220295T1 (hr) 2022-05-13
IL283128B1 (en) 2024-11-01

Similar Documents

Publication Publication Date Title
CO2021007993A2 (es) Compuestos de 2‐formil‐3‐hidroxifeniloximetilo capaces de modular la hemoglobina
MX2015011448A (es) Compuestos y sus usos para modular la hemoglobina.
MX378131B (es) Compuestos y sus usos para modular la hemoglobina.
UY38685A (es) Moduladores de la vía de tensión integrada
CL2018003142A1 (es) Moduladores de la vía de estrés integrada
MX2015011445A (es) Compuestos y usos de estos para la modulacion de la hemoglobina.
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
UY37617A (es) Moduladores de la proteína reguladora de la conductancia transmembrana en fibrosis quística y métodos de empleo
CL2021003257A1 (es) Pirazolo-piridinas heteroaromáticas sustituidas y su uso como moduladores del receptor glun2b.
UY35425A (es) Compuestos y sus usos en la modulación de la hemoglobina
MX2019000588A (es) Moduladores de la somatostatina y usos de los mismos.
DOP2021000251A (es) Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b
CL2019000115A1 (es) Compuestos y métodos para la modulación de smn2.
MX2020009602A (es) Formulaciones de pulverizacion de epinefrina.
GT201400222A (es) Agentes para tratar trastornos que implican la modulación de receptores de rianodina
NI201700154A (es) Moduladores alostéricos positivos de
BR112022008287A2 (pt) Métodos de tratamento usando um modulador de mtorc1
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
CL2021000930A1 (es) Piridazinas novedosas
MX2024003249A (es) Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona.
CO2019008657A2 (es) Composición intranasal que comprende betahistina
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
BR112022019423A2 (pt) Moduladores de hemoglobina
UA98759U (uk) Спосіб друкування нанофотонних елементів активних і розумних паковань